GW786034 in Treating Patients With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2002-12-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the safety and tolerability of GW786034 in patients with advanced solid tumors.
* Determine the maximum tolerated dose of this drug in these patients.
* Determine the pharmacokinetics of this drug in these patients.
* Determine the clinical response in patients treated with this drug.
* Evaluate the effect of this drug on biomarkers of angiogenesis activity in order to estimate activity and to determine the minimum biologically active dose in these patients.

OUTLINE: This is an open-label, nonrandomized, dose-escalation, multicenter study.

Patients receive oral GW786034 twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.

Cohorts of 2-6 patients receive escalating doses of GW786034 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 21 days.

PROJECTED ACCRUAL: Approximately 30-50 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unspecified Adult Solid Tumor, Protocol Specific

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

unspecified adult solid tumor, protocol specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pazopanib hydrochloride

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed advanced solid tumor
* Refractory to standard therapy or for which no standard therapy exists
* No untreated leptomeningeal or brain metastases

* Previously treated brain metastases are allowed if currently asymptomatic and patient is off steroids and antiseizure medications for more than 3 months before study entry

PATIENT CHARACTERISTICS:

Age

* 21 and over

Performance status

* Karnofsky 70-100%

Life expectancy

* At least 12 weeks

Hematopoietic

* Absolute granulocyte count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* Hemoglobin at least 9 g/dL

Hepatic

* Bilirubin no greater than 1.5 mg/dL
* AST and ALT no greater than 2 times upper limit of normal (ULN) (5 times ULN if tumor involvement)

Renal

* Creatinine clearance at least 60 mL/min

Cardiovascular

* No uncontrolled hypertension (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg on 2 consecutive measurements separated by 1 week)
* No arterial or venous thrombosis (including cerebrovascular accident) within the past 3 months
* No myocardial infarction within the past 3 months
* No unstable angina within the past 3 months
* No cardiac angiopathy or stenting within the past 3 months
* No cardiac pacemaker

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 21 days after study treatment
* Able to swallow and retain oral medication
* Good venous access
* No prior or concurrent gastrointestinal disease
* No prior or concurrent condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs
* No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug
* No other unstable, pre-existing major medical condition
* No orthopedic pins or rods or other embedded metal that would preclude undergoing an MRI
* No psychological, familial, sociological, or geographical condition that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

* More than 4 weeks since prior immunotherapy
* Concurrent epoetin alfa allowed
* No concurrent anticancer biologic therapy

Chemotherapy

* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
* No concurrent anticancer cytotoxic chemotherapy

Endocrine therapy

* See Disease Characteristics
* More than 4 weeks since prior hormonal or steroid therapy (other than replacement)
* No concurrent anticancer hormonal therapy (except for replacement)
* No concurrent dexamethasone or prednisone

Radiotherapy

* More than 4 weeks since prior radiotherapy
* No concurrent anticancer radiotherapy

Surgery

* More than 4 weeks since prior major surgery
* No concurrent surgery for cancer

Other

* Recovered from prior therapy
* More than 4 weeks since prior investigational agents
* More then 28 days since prior alteration of antihypertensive medications
* Concurrent bisphosphonates allowed
* No other concurrent anticancer therapy
* No concurrent antidepressants (e.g., amitriptyline, fluoxetine, or fluvoxamine)
* No concurrent oral hypoglycemics (e.g., glipizide, glyburide, rosiglitazone, or tolbutamide)
* No concurrent therapeutic anticoagulation (e.g., warfarin at therapeutic doses)

* Low-dose anticoagulation for prophylaxis allowed
* No concurrent cyclosporine
* No concurrent grapefruit juice
* No concurrent amiodarone, mibefradil, phenobarbital, or pioglitazone
* No concurrent Hypericum perforatum (St. John's Wort)
* No concurrent rifabutin or diethyldithiocarbamate
* No concurrent gestodene, mifepristone, or modafinil
* No concurrent herbal supplements, vitamins, or non-traditional compounds

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Afshin Dowlati, MD

Role: STUDY_CHAIR

Case Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Duke Comprehensive Cancer Center

Durham, North Carolina, United States

Site Status

Case Comprehensive Cancer Center

Cleveland, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009 Jun 15;15(12):4220-7. doi: 10.1158/1078-0432.CCR-08-2740. Epub 2009 Jun 9.

Reference Type RESULT

PMID: 19509175 (View on PubMed)